Costs and Resource Utilization for Diagnosis and Treatment During the Initial Year in a European Inflammatory Bowel Disease Inception Cohort: An ECCO-EpiCom Study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10284040" target="_blank" >RIV/00216208:11110/15:10284040 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1097/MIB.0000000000000250" target="_blank" >http://dx.doi.org/10.1097/MIB.0000000000000250</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/MIB.0000000000000250" target="_blank" >10.1097/MIB.0000000000000250</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Costs and Resource Utilization for Diagnosis and Treatment During the Initial Year in a European Inflammatory Bowel Disease Inception Cohort: An ECCO-EpiCom Study

Popis výsledku v původním jazyce

One thousand three hundred sixty-seven patients were followed, 710 with ulcerative colitis, 509 with Crohn's disease, and 148 with inflammatory bowel disease unclassified. Total expenditure for the cohort was EUR5,408,174 (investigations: EUR2,042,990 [38%], surgery: EUR1,427,648 [26%], biologicals: EUR781,089 [14%], and standard treatment: EUR1,156,520 [22%)]). Mean crude expenditure per patient in Western Europe (Eastern Europe) with Crohn's disease: investigations EUR1803 (EUR2160) (P 1/4 0.44), surgery EUR11,489 (EUR13,973) (P 1/4 0.14), standard treatment EUR1027 (EUR824) (P 1/4 0.51), and biologicals EUR7376 (EUR8307) (P 1/4 0.31). Mean crude expenditure per patient in Western Europe (Eastern Europe) with ulcerative colitis: investigations EUR1189 (EUR1518) (P , 0.01), surgery EUR18,414 (EUR12,395) (P 1/4 0.18), standard treatment EUR896 (EUR798) (P , 0.05), and biologicals EUR5681 (EUR72) (P 1/4 0.51). Conclusions: In this population-based unselected cohort, costs during the fir

Název v anglickém jazyce

Costs and Resource Utilization for Diagnosis and Treatment During the Initial Year in a European Inflammatory Bowel Disease Inception Cohort: An ECCO-EpiCom Study

Popis výsledku anglicky

One thousand three hundred sixty-seven patients were followed, 710 with ulcerative colitis, 509 with Crohn's disease, and 148 with inflammatory bowel disease unclassified. Total expenditure for the cohort was EUR5,408,174 (investigations: EUR2,042,990 [38%], surgery: EUR1,427,648 [26%], biologicals: EUR781,089 [14%], and standard treatment: EUR1,156,520 [22%)]). Mean crude expenditure per patient in Western Europe (Eastern Europe) with Crohn's disease: investigations EUR1803 (EUR2160) (P 1/4 0.44), surgery EUR11,489 (EUR13,973) (P 1/4 0.14), standard treatment EUR1027 (EUR824) (P 1/4 0.51), and biologicals EUR7376 (EUR8307) (P 1/4 0.31). Mean crude expenditure per patient in Western Europe (Eastern Europe) with ulcerative colitis: investigations EUR1189 (EUR1518) (P , 0.01), surgery EUR18,414 (EUR12,395) (P 1/4 0.18), standard treatment EUR896 (EUR798) (P , 0.05), and biologicals EUR5681 (EUR72) (P 1/4 0.51). Conclusions: In this population-based unselected cohort, costs during the fir

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Inflammatory Bowel Diseases

ISSN

1078-0998

e-ISSN

—

Svazek periodika

21

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

121-131

Kód UT WoS článku

000348906500018

EID výsledku v databázi Scopus

2-s2.0-84925827444